CITIC International has raised the target price for HENLIUS to RMB 61.98, expecting significant potential in innovative drug development

阿斯達克財經網
2025.06.25 03:13

招銀國際發表研究報告指，復宏漢霖 (02696.HK) 有能力從一家正在盈利的生物類似藥公司，發展成為生物製劑領域的領先企業，包括 HLX43、HLX22、斯魯利單抗 (Serplulimab) 等多款正在研發的創新藥臨牀數據均表現良好，相信發展潛力龐大， 因此目標價從 20.33 元一舉上調至 61.98 元，維持「買入」評級。

招銀國際認為，復宏漢霖正積極通過與藥企合作，拓展全球生物類似藥業務，旗下「漢曲優」(曲妥珠單抗) 及斯魯利單抗商業化表現強勁，而 HLX14 和 HLX11 的上市許可申請目前正獲 FDA 審查當中，相信可開招海外收入來源。

Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.